Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H23ClFN5O2 |
Molecular Weight | 467.923 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(F)C=C3
InChI
InChIKey=WVUNYSQLFKLYNI-AATRIKPKSA-N
InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+
Molecular Formula | C24H23ClFN5O2 |
Molecular Weight | 467.923 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800014700 | http://www.pharmacodia.com/yaodu/html/v1/chemicals/417346143631ba772ccbbb20c6c4151b.html | https://www.wikigenes.org/e/chem/e/6445562.html | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=352165
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800014700 | http://www.pharmacodia.com/yaodu/html/v1/chemicals/417346143631ba772ccbbb20c6c4151b.html | https://www.wikigenes.org/e/chem/e/6445562.html | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=352165
Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. Pelitinib irreversibly binds covalently to epidermal growth factor receptors, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors. Pelitinib had been in phase II clinical trials for the treatment of non-small cell lung cancer and colorectal cancer. Treatment-emergent adverse events were diarrhea, abdominal pain, gastrointestinal carcinoma, intestinal obstruction and vomiting.
Originator
Sources: http://adisinsight.springer.com/drugs/800014700
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/12502359 16 Oct 2009 Wyeth has been acquired by Pfizer. # Wyeth Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12502359 |
0.08 µM [IC50] | ||
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12502359 |
1.23 µM [IC50] | ||
Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10973323 |
282.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [IC50 23.9185 uM] | ||||
no [EC50 2.1317 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/25988710/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/25988710/ |
no | |||
yes [IC50 3.7908 uM] | ||||
yes | ||||
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16710023
Curator's Comment: The recommended dose of EKB-569 is 25 mg/day when combined with FOLFIRI.
https://www.ncbi.nlm.nih.gov/pubmed/18172273
The maximum tolerated dose of EKB-569 is 75 mg once-daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14749472
Pelitinib has been found to exert a potent anti-proliferative activity against tumor cells overexpressing EGF-R, including NHEK, A431 and MDA-468 cells, with IC50 values of 61 nM, 125 nM and 260 nM respectively; while it has also been found to potently inhibit EGF-induced phosphorylated EGF-R (pEGF-R) in A431 and NHEK cells with IC50 values ranging from 20 nM to 80 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:28:46 GMT 2023
by
admin
on
Fri Dec 15 15:28:46 GMT 2023
|
Record UNII |
X5DWL380Z6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2167
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PP-45
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
100000151604
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
38927
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
6445562
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL607707
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
DTXSID90870294
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
X5DWL380Z6
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
257933-82-7
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
SUB125846
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
C2713
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
DB05524
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY | |||
|
8462
Created by
admin on Fri Dec 15 15:28:46 GMT 2023 , Edited by admin on Fri Dec 15 15:28:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|